Phospho-Jak2 (Tyr1007/1008) Antibody [L12G1]

Application: Reactivity: Human, Mouse, Rat

Lane 1: UT-7, Lane 2: UT-7 (GM-CSF treated)

Usage Information

Dilution
WB1:1000

Application
WB

Reactivity
Human, Mouse, Rat

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
125 kDa

Datasheet & SDS

Biological Description

Specificity
Phospho-Jak2 (Tyr1007/1008) Antibody [L12G1] detects endogenous levels of total Jak2 protein only when it is phosphorylated at Tyr1007/1008.

Clone
L12G1

Synonym(s)
Tyrosine-protein kinase JAK2; Janus kinase 2 (JAK-2); JAK2

Background
Phospho-Jak2 (Tyr1007/1008) represents the critical activation loop phosphorylation within the Janus kinase 2 (Jak2), a non-receptor tyrosine kinase of the Jak family that associates constitutively with cytokine receptors spanning class I and type II families to transduce signals for hematopoiesis, immune regulation, and growth. Jak2 comprises FERM, SH2, and pseudokinase (JH2) domains that maintain autoinhibition until ligand-induced dimerization, with the Tyr1007/1008 motif in the JH1 kinase domain undergoing trans-autophosphorylation to unlock catalytic competency. Ligand binding, such as erythropoietin to EPOR or interferon-γ to IFNGR, clusters receptors, relieving JH2 inhibition and enabling sequential Tyr1007/1008 phosphorylation that amplifies Jak2 activity over 100-fold, recruiting SH2-domain proteins like STAT1/3/5 for tyrosine phosphorylation, dimerization, and nuclear translocation to drive transcription of target genes including SOCS feedback inhibitors, IRF1, and BCL-XL. This cascades through the Jak2-STAT axis with PI3K-Akt and MAPK branches via receptor docking sites, while negative regulation by PTPN6/SHP1 dephosphorylates the loop and SOCS3 binds phosphorylated Tyr221 to attenuate signaling duration. Phospho-Tyr1007/1008 governs erythroid maturation, Th1 differentiation, and megakaryocyte development, positioning it as a direct pharmacodynamic marker for researchers assessing cytokine pathway fidelity in primary hematopoietic cultures or dissecting hypersensitivity in CRISPR-edited cell lines. Dysregulation through the V617F mutation causes constitutive activation in myeloproliferative neoplasms like polycythemia vera.

Background

Phospho-Jak2 (Tyr1007/1008) represents the critical activation loop phosphorylation within the Janus kinase 2 (Jak2), a non-receptor tyrosine kinase of the Jak family that associates constitutively with cytokine receptors spanning class I and type II families to transduce signals for hematopoiesis, immune regulation, and growth. Jak2 comprises FERM, SH2, and pseudokinase (JH2) domains that maintain autoinhibition until ligand-induced dimerization, with the Tyr1007/1008 motif in the JH1 kinase domain undergoing trans-autophosphorylation to unlock catalytic competency. Ligand binding, such as erythropoietin to EPOR or interferon-γ to IFNGR, clusters receptors, relieving JH2 inhibition and enabling sequential Tyr1007/1008 phosphorylation that amplifies Jak2 activity over 100-fold, recruiting SH2-domain proteins like STAT1/3/5 for tyrosine phosphorylation, dimerization, and nuclear translocation to drive transcription of target genes including SOCS feedback inhibitors, IRF1, and BCL-XL. This cascades through the Jak2-STAT axis with PI3K-Akt and MAPK branches via receptor docking sites, while negative regulation by PTPN6/SHP1 dephosphorylates the loop and SOCS3 binds phosphorylated Tyr221 to attenuate signaling duration. Phospho-Tyr1007/1008 governs erythroid maturation, Th1 differentiation, and megakaryocyte development, positioning it as a direct pharmacodynamic marker for researchers assessing cytokine pathway fidelity in primary hematopoietic cultures or dissecting hypersensitivity in CRISPR-edited cell lines. Dysregulation through the V617F mutation causes constitutive activation in myeloproliferative neoplasms like polycythemia vera.

References
https://pubmed.ncbi.nlm.nih.gov/19364823/ https://pubmed.ncbi.nlm.nih.gov/15143188/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%